GET DAILY SIGNALSBeyond Air (XAIR) Consolidates in Low Single Digits Amid Regulatory Watch and Record Revenue
Key Takeaways
- Beyond Air shares have traded in a volatile range around the $2–$3 level over the past month, with the trailing 30-day move roughly flat at approximately -5% despite sharp single-day swings around the company's quarterly report.
- The company reported record quarterly revenue of $2.3 million, up roughly 28% year over year, and reaffirmed its full-year revenue guidance.
- The second-generation LungFit PH system remains under FDA review, with audit readiness expected around mid-December—a key near-term catalyst for the stock.
- Analysts tracked by major financial data providers rate XAIR a consensus "Buy" with a 12-month average price target of $20.
- Beyond Air held about $18.5 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026, while still reporting a net loss.
- The company has streamlined its portfolio, agreeing to sell its controlling interest in NeuroNOS and evaluating strategic options for Beyond Cancer.
- For additional details on valuation and expectations, explore Price Targets, Earnings, and Forecast pages.
- Discover how automated strategies approach this and other names on the Trending AI Robots page.
Market Snapshot for XAIR
Beyond Air, Inc. trades on the Nasdaq under the ticker XAIR as a micro-cap healthcare name, with a 52-week range spanning roughly $2.05 to $53.20—a wide band that reflects both a significant prior de-rating and persistent volatility. Over the trailing month, the stock has largely consolidated in the low single digits, and its recent moves have been driven more by company-specific regulatory and commercial news than by broad market trends. Trading volume has been relatively light on most sessions, with occasional spikes around disclosures, which can amplify percentage swings in a thinly traded name. Investors tracking XAIR are primarily focused on execution of its commercial launch and the outcome of an active regulatory review rather than on sector rotation or macroeconomic positioning. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Business Overview and Competitive Edge
Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on harnessing nitric oxide (NO) to treat respiratory illnesses, neurological disorders, and solid tumors. Its flagship product, LungFit PH, is a cylinder-free, phasic flow generator and delivery system that generates nitric oxide on demand from ambient air. The system has received FDA approval and CE Mark for the treatment of term and near-term neonates with persistent pulmonary hypertension of the newborn (PPHN) associated with hypoxic respiratory failure.
The company's core competitive distinction is the elimination of high-pressure nitric oxide cylinders, which it argues reduces inventory and storage burdens, improves safety by removing NO2 purging steps, and creates operational advantages in hospital settings. Beyond its lead product, the company is developing LungFit PRO for viral lung infections and LungFit GO for nontuberculous mycobacterial (NTM) disease, as well as an ultra-high concentration nitric oxide (UNO) program in Phase 1 for solid tumors and neuronal nitric oxide synthase (nNOS) inhibitor candidates for neurological conditions. The business operates through the Beyond Air, Beyond Cancer, and NeuroNOS segments and distributes internationally through partnerships covering more than 40 countries.
Recent Developments Shaping Sentiment
Several verified developments over the past month have shaped investor sentiment. On November 11, 2026, the company reported results for the quarter ended September 30, 2026, posting record quarterly revenue of $2.3 million, up approximately 28% year over year and 31% sequentially. Gross margin improved to roughly 8% from negative 16% in the prior-year period, while net loss attributable to common stockholders was $7.8 million, or $3.76 per share.
Management reaffirmed revenue guidance of $8 million for calendar year 2026 and $16 million to $18 million for calendar year 2027, the latter incorporating anticipated revenue from the second-generation LungFit PH system pending FDA approval. That premarket approval (PMA) supplement remains under review, with the company expecting to complete audit readiness in mid-December ahead of FDA inspection and a final decision. During the quarter, LungFit GO also received FDA breakthrough device designation for NTM pulmonary disease, though the company indicated it does not currently plan to allocate resources to further LungFit GO development in 2027. The company also announced a definitive agreement to sell its controlling interest in NeuroNOS Israel and said it is evaluating strategic arrangements for Beyond Cancer.
2026 Outlook and Key Areas to Monitor
Looking ahead, the most consequential catalyst for XAIR is the FDA's decision on the second-generation LungFit PH PMA supplement, including the requested labeling for patient transport. A favorable outcome would expand the company's addressable market and support the calendar year 2027 revenue guidance of $16 million to $18 million. Investors should also monitor commercial execution metrics such as pipeline growth, new account wins, renewal rates, and gross margin progression, as well as the company's international expansion.
Key risks include the company's history of losses, a cash position that management has acknowledged may be insufficient to fund operations through profitability, and uncertainty around the timing and outcome of regulatory review. The transition to a December 31 fiscal year-end, the closing of the NeuroNOS transaction, and any strategic outcome for Beyond Cancer could further influence sentiment. These factors make regulatory milestones, capital position, and revenue execution the central themes to watch into 2026. From what I see, the regulatory timeline stands out as particularly important here.
Using AI Tools in My Research Process
In my analysis of names like XAIR, I often turn to Tickeron’s AI tools for additional perspective on patterns and automated strategies. The Trending AI Robots page, for instance, curates a selection of AI-powered trading bots from a platform that hosts hundreds of automated strategies trading thousands of tickers. Only top-performing and most relevant bots are featured, giving users a focused view of systems currently drawing attention. The bots vary in trading strategy, timeframe, and performance metrics, so the page serves as a discovery tool rather than a one-size-fits-all recommendation. For traders interested in data-driven approaches, it offers a practical starting point for exploring how automation applies across a broad universe of securities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
XAIR's RSI Oscillator ascending out of oversold territory
The RSI Indicator for XAIR moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In 35 of the 42 cases the stock moved higher. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on XAIR as a result. In 81 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +13.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where XAIR advanced for three days, in 174 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 44 cases where XAIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XAIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
XAIR broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XAIR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.084) is normal, around the industry mean (4.142). P/E Ratio (-0.036) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.213) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. XAIR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XAIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical device company, which engages in the development of nitric oxide (NO) generator and delivery system.
Industry MedicalNursingServices
Advertisement